Arecor & TRx BioSciences Partners for Oral GLP-1 Therapy

Arecor & TRx BioSciences Partners for Oral GLP-1 Therapy

By, Admin 14 March 2024

Arecor and TRx BioSciences Establish Partnership for Advancing Oral GLP-1 Therapy with Improved Bioavailability

Arecor Therapeutics plc (AIM: AREC), a biopharmaceutical company focused on advancing modern therapies for improved health outcomes, has teamed up with TRx Biosciences Limited, a leader in innovative lipid technology for oral drug delivery. Together, they have announced a research collaboration aimed at formulating an oral glucagon-like peptide-1 (GLP-1) receptor agonist product.

GLP-1 Receptor Agonists: Funds & Challanges

  • GLP-1 receptor agonists are crucial for managing type 2 diabetes and obesity. 
  • The global market for these treatments is projected to reach $80-$100+ billion by 2030. 
  • However, delivering these drugs orally presents significant challenges due to the digestive system's proteolytic nature, resulting in reduced bioavailability. 
  • Currently, injection remains the primary delivery method, limiting patient adoption, compliance, and usage.
  • Aim for thi collaboration
  • The only oral GLP-1 receptor agonist available to patients is Novo Nordisk’s semaglutide (Rybelsus®), which boasts less than 1% oral bioavailability. 
  • To address this issue, Arecor and TRx Biosciences plan to utilize TRx Biosciences’ LipiCore™ oral delivery technology along with Arecor’s formulation platform, Arestat™. 
  • This collaboration aims to develop an oral GLP-1 receptor agonist product with improved physicochemical properties to achieve higher oral bioavailability and stability.

Arecor CEO on Challanges

  • Sarah Howell, CEO of Arecor, highlighted the ongoing challenges in oral delivery for GLP-1 receptor agonists and expressed optimism in leveraging Arecor's Arestat™ technology alongside TRx Biosciences' expertise to develop an enhanced oral product. 
  • Dr. Robin Bannister, CEO of TRx Biosciences, emphasized the importance of effective oral peptide delivery and the potential of combining LipiCore™ with Arecor's platform to unlock novel oral uptake channels and protect peptides during gastrointestinal transit.

Novel GLP-1 Receptor Agonist

  • The collaboration aims to extend beyond the initial GLP-1 receptor agonist program to develop additional oral peptide products, potentially targeting obesity-related health conditions and other therapeutic areas. 
  • Success in this endeavor could revolutionize oral peptide therapy, providing patients with more convenient and effective treatment options.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!